Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quantum chemical treatment, electronic energy in various solvents, spectroscopic, molecular docking and dynamic simulation studies of 2-amino-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide: A core of anticancer drug.
Verma NL, Kumar S, Kumar M, Pal J, Sharma D, Lalji RSK, Chahal M, Kant H, Rathor N, Javed S, Jaiswar G. Verma NL, et al. Among authors: rathor n. Spectrochim Acta A Mol Biomol Spectrosc. 2025 Feb 5;326:125263. doi: 10.1016/j.saa.2024.125263. Epub 2024 Oct 9. Spectrochim Acta A Mol Biomol Spectrosc. 2025. PMID: 39413608
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by Sex.
Verma S, Colhoun HM, Dicker D, Hovingh GK, Kahn SE, Kautzky-Willer A, Lingvay I, Plutzky J, Rasmussen S, Rathor N, Hoff ST, Lincoff AM. Verma S, et al. Among authors: rathor n. J Am Coll Cardiol. 2024 Oct 22;84(17):1678-1682. doi: 10.1016/j.jacc.2024.08.022. Epub 2024 Aug 30. J Am Coll Cardiol. 2024. PMID: 39217575 Free article. No abstract available.
Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT.
Lingvay I, Deanfield J, Kahn SE, Weeke PE, Toplak H, Scirica BM, Rydén L, Rathor N, Plutzky J, Morales C, Lincoff AM, Lehrke M, Jeppesen OK, Gajos G, Colhoun HM, Cariou B, Ryan D; SELECT Trial Investigators. Lingvay I, et al. Among authors: rathor n. Diabetes Care. 2024 Aug 1;47(8):1360-1369. doi: 10.2337/dc24-0764. Diabetes Care. 2024. PMID: 38907684 Free PMC article. Clinical Trial.
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.
Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, Plutzky J, Node K, Parkhomenko A, Rydén L, Wilding JPH, Mann JFE, Tuttle KR, Idorn T, Rathor N, Lincoff AM. Colhoun HM, et al. Among authors: rathor n. Nat Med. 2024 Jul;30(7):2058-2066. doi: 10.1038/s41591-024-03015-5. Epub 2024 May 25. Nat Med. 2024. PMID: 38796653 Free PMC article. Clinical Trial.
Effect of semaglutide 2.4 mg on physical functioning and weight- and health-related quality of life in adults with overweight or obesity: Patient-reported outcomes from the STEP 1-4 trials.
Rubino D, Bjorner JB, Rathor N, Sharma AM, von Huth Smith L, Wharton S, Wadden T, Zeuthen N, Kolotkin RL. Rubino D, et al. Among authors: rathor n. Diabetes Obes Metab. 2024 Jul;26(7):2945-2955. doi: 10.1111/dom.15620. Epub 2024 May 2. Diabetes Obes Metab. 2024. PMID: 38698650 Clinical Trial.
53 results